🧭 REBEL Rundown
🔑 Key Points
- ⚡Time in VF may be a modifiable resuscitation target, and reductions in VF burden likely contribute to improved survival
- ⏱️Both DSED and VC reduce time in VF as compared to standard defibrillation in refractory VF
- 🔥DSED appears most promising, showing the greatest reduction in time spent in VF, and the greatest improvement in survival to discharge
- 🚑 Future studies are looking to evaluate DSED as the initial management for patients in VF, as opposed to only refractory cases
📝 Introduction
- With over 350,000 annual cases in the US, Out-of-Hospital Cardiac Arrests (OHCA) remain one of the most lethal medical emergencies, with survival rates hovering around just 10%1. Importantly, however, the presence of Ventricular Fibrillation (VF) represents a significant positive predictor of patient survival,2 and there exists a growing literature suggesting that survival could be further improved by reducing time spent in VF between shocks,3 with Awad et. al demonstrating that each minute in VF reduces the odds of achieving ROSC by nearly 20%.4
- Given that current medical management with anti-arrhythmics has shown little benefit with respect to neurologically intact survival,5 alternative defibrillation strategies – namely, Dual Sequential External Defibrillation (DSED) and Vector Change Defibrillation (VC) – have emerged as potential therapeutics to improve management of refractory VF; previous REBEL EM articles have discussed the electrophysiology behind their theoretical benefit, as linked below.
- In this secondary analysis of the DOSE-VF Trial, one of the first RCTs assessing alternative defibrillation strategies in OHCA, the authors reviewed defibrillation files from the initial study to answer whether reduced time in VF between shocks could explain the survival benefits noted in the original RCT.
- With over 350,000 annual cases in the US, Out-of-Hospital Cardiac Arrests (OHCA) remain one of the most lethal medical emergencies, with survival rates hovering around just 10%1. Importantly, however, the presence of Ventricular Fibrillation (VF) represents a significant positive predictor of patient survival,2 and there exists a growing literature suggesting that survival could be further improved by reducing time spent in VF between shocks,3 with Awad et. al demonstrating that each minute in VF reduces the odds of achieving ROSC by nearly 20%.4
🧾 Paper
Cheskes S, et al. The impact of alternate defibrillation strategies on time in ventricular fibrillation. Resuscitation. 2025. PMID: 39970979
Previously Covered On REBEL
⚙️ What They Did
In patients with OHCA with refractory VF, do alternative defibrillation strategies (DSED or VC) reduce the amount of time patients spend in VF between shocks?
- Type of Study: Secondary Analysis of a previously performed cluster-randomized RCT
- Initial timeline: March 2018 to May 2022
- Location: Ontario, Canada
- Initial RCT Brief Methodology:
- In the initial RCT (DOSE-VF), alternate defibrillation methods were compared to standard defibrillation for patients found to be in refractory VF during OHCA
- Six Ontario-based paramedic services were computer randomized to one of three treatment arms: Standard Defibrillation, DSED (Double Sequential External Defibrillation), and VC (Vector Change Defibrillation).
- EMS crossover into another treatment arm occurred every 6 months.
- All patients/treatment groups received standard ACLS and received an initial 3 standard anterolateral shocks until determined to be in refractory VF
- Secondary Analysis Methodology:
- In this secondary analysis of patients enrolled in the DOSE-VF RCT, only patients who received the allocated randomized treatment were included
- Defibrillator data from either the Zoll or LIFEPAK devices were evaluated by two independent reviewers until consensus was achieved on each of the following:
- Time in VF after each standard shock prior to randomization (3 total)
- Time in VF after the 1st, 2nd (if required), and 3rd (if required) shocks post randomization into any of the 3 arms of the trial (6 shocks total)
- No time in VF data was recorded beyond the 6th total shock to mitigate confounding/resuscitation time bias
- Immediate post shock rhythm
- Cases in which there was disagreement on time of VF were decided by consensus of all 4 reviewers
- Analysis
- A Kruskal Wallis test was used to examine differences in median VF time across groups, and post-hoc pairwise comparisons were made using Dunn’s Test with Bonferroni correction
- Kruskal Wallis testing is a method for determining if there are differences between independent groups, but - unlike ANOVA testing - notably does not require the groups to be normally distributed. Essentially, it asks if any of the groups are different from one another
- Once this has been determined, Dunn/Bonferroni post-hoc testing can answer which particular groups differ from one another, and specifically helps to control for false positives.
- Violin plots demonstrating amount of time in VF for each strategy were created to graph probability distributions
- A Kruskal Wallis test was used to examine differences in median VF time across groups, and post-hoc pairwise comparisons were made using Dunn’s Test with Bonferroni correction
Inclusion Criteria:
| Exclusion Criteria:
|
Intervention Group:
| Comparator Group:
|
Primary Outcome:
| Secondary Outcomes:
|
📈 Results:

💥 Critical Results

💪🏽 Strengths
- Minimization of EMS Variability: Although this is a per-protocol analysis, the DOSE-VF trial utilized a cluster-randomized crossover design. This ensures that the data minimizes variability attributable to specific EMS agencies or providers, distinguishing the effect of the shock strategy from the quality of the system delivering it
- Treatment group characteristics: Patient demographics were relatively consistent across treatment arms, with the exception of pre-hospital intubation, where it should be noted the standard group was 37.7%, compared to 49.5% for VC and 43.7% for DSED
- Sample size: For a secondary analysis of this nature requiring significant human evaluation, having 1842 total shocks analyzed should be commended
- Data reliability: Data was obtained directly from the defibrillators themselves as opposed to relying on any EMS recorded data
- Blinding of reviewers: Analysis of defibrillation data was performed by 4 independent reviewers
- Consensus: Each defibrillation file required there to be consensus between both reviewers, and was escalated to the full 4 reviewers in cases of disagreement
- Future oriented/feasibility: Successfully identified a potential modifiable resuscitation target – time in VF – and demonstrated the feasibility of using this metric in future studies
⚠️ Limitations
- External validity: Although not mentioned by the authors, there were concerns regarding the external validity of the initial study due to the speed of the EMS personnel involved; this may result in a blunted effect in other settings where more ischemia has occurred prior to initial interventions
- Selection Bias: This analysis represents a hyper-selected population. First, it utilized a per-protocol rather than intention-to-treat population, excluding patients where the intervention failed to be delivered. Second, it further excluded shocks with uninterpretable data or artifacts. While necessary for a mechanistic analysis, this dual layer of selection filters out the logistical realities of chaotic resuscitations, potentially biasing the results toward ideal scenarios.
- Bystander CPR: Similarly, rates of bystander CPR dwarf typical US numbers, which likely improved outcomes, though this should affect all groups equally
- EMS blinding: There was no blinding to the intervention group for EMS, which could impact how the resuscitation was managed outside of the defibrillation strategy
- Researcher bias: As a secondary analysis, the authors have knowledge of the original outcomes, introducing new bias and potentially amplifying biases from the initial study
- Study length: The DOSE-VF RCT ended early due to COVID, which could exaggerate intervention impacts (as seen by the narrow fragility indices in the original study)
- Data collection: Although the data continued to show a benefit for DSED, no rhythm analysis was performed beyond shock #6
- Lost data: 4 patients had no defibrillation data, and 4 did not have shock type recorded
- Demographic data/BMI: BMI data was not recorded for the treatment groups. While the data regarding defibrillation success rate and obesity is mixed,6 impedance is directly correlated with obesity, and dual shock cardioversion has been shown to be more effective than single shock cardioversion for obese patients.7
- Other PMH: Although less directly relevant than BMI, no information was provided regarding other past medical history
- Mechanistic certainty: While this study does support the original findings,it cannot show any direct causation between time spent in VF and improved outcomes
- Time in VF calculation: Data was calculated by subtracting time not in VF from a base 120 second rhythm check, but it is unlikely that rhythm checks consistently occurred at exactly 2 minute intervals
- Missed opportunity: Only double sequential external defibrillation was used; it is possible there could have been even more profound results with simultaneous defibrillation
🗣️ Discussion
Mechanism Matters
- Without fully rehashing the strengths of the DOSE-VF RCT, this secondary analysis does a commendable job at attempting to establish the mechanism behind the survival benefits described for VC and DSED in the original trial. Perhaps more noteworthy, however, is identifying the feasibility of using time in VF as a modifiable resuscitation target. While the recurrence of VF well before rhythm checks is to be expected,8 the clear trend in reduction of time in VF with DSED and VC can reasonably explain improved outcomes. Even with active CPR, ongoing VF contributes to cardiac ischemia, which, in turn, results in myocardium that is progressively more difficult to defibrillate.9
- While this study falls short of demonstrating causality between time in VF and improved survival, the plausibility is more than enough to influence clinical practices. Furthermore, the results are congruent with emerging (though underpowered) data suggesting the benefits of alternate defibrillation strategies by both increasing total joules and more directly engaging the left ventricle, though meta-analyses to date show the need for more studies similar to the DOSE-VF RCT in order to clearly demonstrate benefit. 10-13
- It is additionally important to recognize that all of the shocks delivered in the DSED arm of this trial were intentionally performed sequentially with a short delay between shocks, as opposed to simultaneously. With the understanding that defibrillation is probabilistic – that is, defibrillation success increases with the amount of joules delivered – there is reason to believe that simultaneous shocks could be more effective at resolving arrhythmias. 7,9 While the authors understandably included this delay in order to reduce the theoretical risk of device damage, it nonetheless represents a missed opportunity to evaluate this modality.16,17 This is notable, as animal models suggest that some sequential time delays (50ms in particular) can actually result in worse outcomes by retriggering VF if the initial shock was successful.18
- Without fully rehashing the strengths of the DOSE-VF RCT, this secondary analysis does a commendable job at attempting to establish the mechanism behind the survival benefits described for VC and DSED in the original trial. Perhaps more noteworthy, however, is identifying the feasibility of using time in VF as a modifiable resuscitation target. While the recurrence of VF well before rhythm checks is to be expected,8 the clear trend in reduction of time in VF with DSED and VC can reasonably explain improved outcomes. Even with active CPR, ongoing VF contributes to cardiac ischemia, which, in turn, results in myocardium that is progressively more difficult to defibrillate.9
Battle of the Vectors
- With respect to the rhythm analysis, the data does appear to support the author’s assertion that the difference in time in VF is secondary to the type of shock received. Although the decision to run this as a per-protocol study offers reduced protection against randomization, the baseline rhythms of each protocol were nearly identical, and remarkably few defibrillation files were lost given the size of the study. Likewise, there is a clear reduction in time spent in VF after intervention which is consistent from shock to shock, and although there are legitimate concerns regarding the external validity of DOSE-VF due to excellent EMS care, this is likely only to affect the magnitude of the impact, rather than the presence of it at all.
- From a clinical standpoint, it is difficult not to notice the clear difference in times between the VC and DSED treatment arms, and a 15 second difference between the two feels like it could be relevant to patient outcomes. This study is unfortunately too underpowered to demonstrate statistical significance between the two, but personally, a trend here is more than enough to be practice changing and lead to DSED being used over VC.
- In a resource-rich setting where obtaining a second defibrillator is easy, the potential upside is clear and the downsides are few, with just the (low) theoretical risk of damage to the defibrillator to consider16,17. For this reason and to minimize delays later in care, posterior pads should likely be applied during initial transfer onto the ED stretcher for any patient that was noted to be in VF prior to arrival.
- Although there are case reports of defibrillator damage from simultaneous shocks, this risk appears to be relatively rare at a reported 0.4%, and it can be further reduced by ensuring a perpendicular angling of the shock vectors.16 Those who remained concerned, however, may be reassured that zero devices were damaged during the DOSE-VF trial, which used sequential defibrillation. Likewise, a retrospective review of over 1000 EMS cases revealed that 100% of device damage occurred during simultaneous, not sequential defibrillation attempts, indicating the risk is likely appreciably lower with intentional delay.17
- Further studies, however, are certainly needed to justify two defibrillators being available in settings where this would be cost prohibitive, and device damage even more so. In these scenarios, VC defibrillation appears to be ideal, as both the survival benefit and the reduction in time spent in VF are still quite appreciable for the VC group . Although taking the time to re-orient the pads would decidedly prolong a pulse check and reduce chest compression fracture, it seems likely that this effort represents a net benefit for patients in refractory VF by more directly orienting shocks towards the ischemic left ventricle.
Future Directions
- While the authors themselves touch on some aspects of this, there are multiple conclusions that can be drawn from reducing time in VF from 113 seconds to 83 seconds with DSED after shock #4. The most obvious of these is the suggestion that DSED should be employed as early as possible in VF, well before it could be considered refractory. Further studies are needed to mathematically back that decision (and are currently in progress), but earlier initiation of DSED is more than reasonable based on current data given the potential upside.
- If you fully buy into the idea that time in VF directly leads to worse outcomes, however, there is the more interesting implication that standard ACLS should be modified in refractory VF. With medical options being largely ineffective and 83 out of 120 seconds being VF, should we be less aggressively prioritizing chest compression fraction in favor of more frequent rhythm checks and shocks? Personally, the data here is not convincing enough to change clinical practices in this regard, but should remain a topic of conversation.
📘 Author's Conclusion
“Among patients enrolled in the DOSE VF RCT, time in VF was shorter for DSED and VC shocks compared to standard shocks….[t]he lower time in VF associated with alternate defibrillation strategies provides insight into the survival benefit noted during the trial.”
💬 Our Conclusion
The findings of this secondary analysis lend to the idea that alternative defibrillation strategies can improve mortality in refractory VF, and newer literature likewise appears to support this conclusion. DSED in particular shows promise, and although there is not yet enough evidence to definitively say that it is superior to standard or AP shocks, the combination of a relatively low risk of harm with a potentially significant upside that is mechanistically sound, should push DSED to be the standard for refractory VF in the ED setting. While the time spent in VF data suggests that the current 2-minute rhythm check may need to be re-evaluated, there does not yet exist enough evidence to change clinical practice
🚨 Clinical Bottom Line
DSED and VC significantly reduce VF burden and improve survival compared to standard defibrillation. Prioritize DSED for refractory VF as it demonstrates the strongest signal for benefit, using VC when DSED is not feasible.
📚 References
- Virani SS, et al.
Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020.
PMID: 36695182 - Abrams HC,et al.
A composite model of survival from out-of-hospital cardiac arrest using the Cardiac Arrest Registry to Enhance Survival (CARES). Resuscitation. 2013.
PMID: 23603289 - Berdowski J, et al.
Time in recurrent ventricular fibrillation and survival after out-of-hospital cardiac arrest. Circulation. 2010.
PMID: 20805427 - Awad E, et al.
The impact of time to defibrillation on return of spontaneous circulation in out-of-hospital cardiac arrest patients with recurrent shockable rhythms. Resuscitation. 2024
PMID: 38901663 - Kudenchuk PJ, et al.
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2016.
PMID: 27043165 - White RD, et al.
Body weight does not affect defibrillation, resuscitation, or survival in patients with out-of-hospital cardiac arrest treated with a nonescalating biphasic waveform defibrillator. Crit Care Med. 2004.
PMID: 15508666 - Aymond JD, et al.
Dual vs Single Cardioversion of Atrial Fibrillation in Patients With Obesity: A Randomized Clinical Trial. JAMA Cardiol. 2024.
PMID: 38776097 - Pandit SV, Lampe JW, Silver AE.
Recurrence of ventricular fibrillation in out-of-hospital cardiac arrest: Clinical evidence and underlying ionic mechanisms. J Physiol. 2024.
PMID: 38661672 - Trayanova NA, et al.
Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation. Physiol Rev. 2024.
PMID: 38153307 - Lupton JR, et al.
Initial Defibrillator Pad Position and Outcomes for Shockable Out-of-Hospital Cardiac Arrest. JAMA Netw Open. 2024.
PMID: 39250154 - Kim HE, Lee KJ, Jo YH, et al.
Refractory Ventricular Fibrillation Treated with Double Simultaneous Defibrillation: Pilot Study. Emerg Med Int. May 27 2020.
PMID: 32566304 - Ristagno G, Yu T, Quan W, Freeman G, Li Y.
Comparison of defibrillation efficacy between two pads placements in a pediatric porcine model of cardiac arrest. Resuscitation. 2012.
PMID: 22198420 - Abuelazm MT, et al.
Defibrillation strategies for refractory ventricular fibrillation out-of-hospital cardiac arrest: A systematic review and network meta-analysis. Ann Noninvasive Electrocardiol. 2023
PMID: 37482919 - Cheskes S, et al.
Double sequential external defibrillation for refractory ventricular fibrillation: The DOSE VF pilot randomized controlled trial. Resuscitation. 2020;150:178-184.
PMID: 32084567 - Cheskes S, et al.
The impact of alternate defibrillation strategies on time in ventricular fibrillation. Resuscitation. 2025.
PMID: 39970979 - Gerstein NS, et al.
External Defibrillator Damage Associated With Attempted Synchronized Dual-Dose Cardioversion. Ann Emerg Med. 2018;71(1):109-112.
PMID: 28559035 - Drennan IR, et al.
A survey of the incidence of defibrillator damage during double sequential external defibrillation for refractory ventricular fibrillation. Resusc Plus. 2022;11:100287.
PMID: 36105412 - Taylor TG, et al.
An investigation of inter-shock timing and electrode placement for double-sequential defibrillation. Resuscitation. 2019;140:194-200.
PMID: 31063842
Post Peer Reviewed By: Mark Ramzy, DO (X/IG: @MRamzyDO), and Marco Propersi, DO (X: @Marco_Propersi)
👤 Meet the Authors
Evan Genova MD
Dorian Alexander, MD
🔎 Your Deep-Dive Starts Here
REBEL Cast Ep113: Defibrillation Strategies for Refractory Ventricular Fibrillation
Background Information: Double external defibrillation (DED) is an intervention often used to treat ...
The DOSE VF Pilot RCT: Double Sequential External Defibrillation for Refractory Ventricular Fibrillation
Background Information: Refractory ventricular fibrillation (RVF) is a complication of cardiac arrest defined ...
Dual Sequential Defibrillation (DSD)
Background: In the United States 424,000 out of hospital cardiac arrests occur per year ...
REBEL Cast Episode 28: Refractory Ventricular Fibrillation
Background: Welcome back to the September 2016 REBEL Cast. We are back with ...
Beyond ACLS: Dual Simultaneous External Defibrillation
Background: Out-of-hospital cardiac arrest (OHCA) occurs in the United States at a rate ...







